Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2014 Q1- Text added to 2014 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
abicipar, Ackman, acknowledged, actuation, advisor, AmerisourceBergen, amortizable, calendar, cataract, CHMP, commenced, complementary, consummate, content, context, daily, deliver, depression, dexamethasone, disrupt, disruptive, distract, DME, efficiency, effort, elevated, entitled, failed, failure, false, half, headcount, highest, holder, hostile, insider, intraocular, intravitreal, Junior, key, labeling, labor, mcg, Medicinal, medicine, member, merger, mg, neovascular, nonfinancial, Novadur, organizational, ownership, pain, pegol, Pershing, polymer, preferred, prejudice, pressure, prioritize, promulgated, proxy, pseudophakic, receipt, rescinding, resolution, Responding, role, satisfaction, scope, SempranaTM, situation, solid, source, Square, summary, sustain, takeover, target, tender, therapy, topline, turmoil, unsolicited, unsuitable, vacant, Valeant, validity, vision, wide, William, workforce
Removed:
allergic, China, crow, denied, expander, feet, GlaxoSmithKline, itching, prevention, small
Valuein 2014 Q1 filing- Value in 2014 Q2 filing
Original filings
Filing view